Query: stroke

Filtered By:
Condition: Heart Failure
Procedure: Lung Transplant

This page shows you your search results in order of date.

Order by Relevance | Date

Total 63 results found since Jan 2013.

Predicting the survivals and favorable neurologic outcomes after targeted temperature management by artificial neural networks
CONCLUSIONS: The ANN-based models achieved good performance to predict the survival and favorable neurologic outcomes after TTM. The models proposed have clinical value to assist in decision-making.PMID:34330620 | DOI:10.1016/j.jfma.2021.07.004
Source: J Formos Med Assoc - July 31, 2021 Category: General Medicine Authors: Wei-Ting Chiu Chen-Chih Chung Chien-Hua Huang Yu-San Chien Chih-Hsin Hsu Cheng-Hsueh Wu Chen-Hsu Wang Hung-Wen Chiu Lung Chan Source Type: research

Cerebral Vasoreactivity in HeartMate 3 Patients
While rates of stroke have declined with the HeartMate3 (HM3) continuous flow (CF) left ventricular assist device (LVAD), the impact of non-pulsatile flow and artificial pulse physiology on cerebrovascular function is not known. We hypothesized that improved hemodynamics and artificial pulse physiology of HM3 patients would augment cerebrovascular metabolic reactivity (CVR) compared with HeartMate II (HMII) CF-LVAD and heart failure (HF) patients.
Source: The Journal of Heart and Lung Transplantation - May 21, 2021 Category: Transplant Surgery Authors: Eric J. St öhr, Ruiping Ji, Koichi Akiyama, Giulio Mondellini, Lorenzo Braghieri, Alberto Pinsino, John R. Cockcroft, Melana Yuzefpolskaya, Amrin Amlani, Veli K. Topkara, Hiroo Takayama, Yoshifumi Naka, Nir Uriel, Koji Takeda, Paolo C. Colombo, Barry J. Tags: Original Research Article Source Type: research

Bridge from Central Extracorporeal Life Support to Durable LVAD in Acute Heart Failure Elevates a Risk of Stroke Long-Term
This study aimed to review outcomes of this bridge strategy from central ECLS to durable LVAD, as compared to those of primary LVAD implantation.
Source: The Journal of Heart and Lung Transplantation - March 20, 2021 Category: Transplant Surgery Authors: K. Tonai, S. Fukushima, N. Tadokoro, N. Fukushima, T. Fujita Tags: (994) Source Type: research

Arterial Pulsatility in Patients with Continuous Flow Left Ventricular Assist Device Support: Comparing Velocity and Mean Arterial Pressure
An increasing number of end-stage heart failure patients are supported by continuous-flow Left Ventricular Assist Devices (cfLVADs) as a bridge to heart transplantation. Accurate assessment of arterial pulsatility remains a challenge because of diminished pulse pressure, which itself can be associated with adverse events such as gastrointestinal bleeding and stroke. Our study investigates the value of simultaneous arterial pressure and arterial blood velocity assessment in cfLVAD patients.
Source: The Journal of Heart and Lung Transplantation - March 20, 2021 Category: Transplant Surgery Authors: S. Emmanuel, A. Adji, D. Robson, P. Jain, C. Hayward Tags: 1138 Source Type: research

079 Assessing Arterial Pulsatility in Patients With Continuous Flow Left Ventricular Assist Device Support
An increasing number of end-stage heart failure patients are supported by continuous-flow Left Ventricular Assist Devices (cfLVADs) as a bridge to heart transplantation. In these patients, accurate assessment of arterial pulsatility remains a challenge because of diminished pulse pressure, which itself can be associated with adverse events such as gastrointestinal bleeding and stroke. Our study investigates the value of simultaneous arterial pressure and arterial flow velocity assessment in cfLVAD patients.
Source: Heart, Lung and Circulation - November 8, 2020 Category: Cardiology Authors: A. Adji, S. Emmanuel, P. Jain, C. Hayward Source Type: research

Cardiac Transplantation for Cancer Involving the Heart
Cardiac Cancer (CC) that arises from or involves the heart can present as heart failure, chest pain, stroke or another thromboembolic event. Although patients with CC have limited treatment options, in other organ cancers such as hepatocellular carcinoma, liver transplant improves 5-year overall survival in carefully selected patients1. For CC, however, the benefit of replacing the cancerous heart is uncertain because one-year survival is generally estimated around 50% after this rare operation.
Source: The Journal of Heart and Lung Transplantation - May 23, 2020 Category: Transplant Surgery Authors: Matthew Wingo, Andreas R. de Biasi, Yasuhiro Shudo, Vijaya Bharathi, Anthony Blackburn, Mario Gaudino, Leonard N. Girardi, Y. Joseph Woo Tags: Research Correspondence Source Type: research

Risk assessment in PAH using quantitative CMR tricuspid regurgitation: relation to heart catheterization
ConclusionsA clear trend towards worse outcome with larger TRV or TR% was shown; however, the number of events was insufficient for significant outcome differences. Prognostic value of quantitative TR should be investigated in a larger multicentre cohort. Effective RV ejection fraction may be considered an improved measure of RV function in PAH.
Source: ESC Heart Failure - May 5, 2020 Category: Cardiology Authors: Erik Hedstr öm, Anna Bredfelt, Göran Rådegran, Håkan Arheden, Ellen Ostenfeld Tags: Original Research Article Source Type: research

Quantifying the Impact from Stroke During Support with Continuous Flow Ventricular Assist Devices: An STS INTERMACS Analysis
Adverse events, and in particular strokes, during continuous flow durable left ventricular assist devices (LVAD) remain the major barrier to greater application among patients with ambulatory advanced heart failure.
Source: The Journal of Heart and Lung Transplantation - April 20, 2020 Category: Transplant Surgery Authors: James K. Kirklin, David C. Naftel, Susan L. Myers, Francis D. Pagani, Paolo C. Colombo Tags: Original Clinical Science Source Type: research

Two-Year Outcomes in HeartMate 3 versus HeartWare HVAD Patients Implanted as Destination Therapy
The ENDURANCE trial demonstrated noninferiority of the intrapericardial centrifugal-flow HeartWare HVAD compared to the axial-flow HeartMate II left ventricular assist device (LVAD) regarding survival in patients with advanced heart failure ineligible for heart transplantation, but stroke was more common. Most recently, the MOMENTUM 3 trial demonstrated superiority of the intrathoracic, fully magnetically levitated centrifugal-flow HeartMate 3 (HM3) LVAD compared to the HeartMate II. A clinical trial evaluating the HM3 and HVAD has not been performed, therefore the purpose of this study was to compare outcomes between these two devices.
Source: The Journal of Heart and Lung Transplantation - March 31, 2020 Category: Transplant Surgery Authors: L. Coyle, C. Gallagher, L. Kukla, R. Paliga, R. Siemeck, G. Yost, M. Dia, A. Tatooles Tags: (1039) Source Type: research

Blood Conservation Strategy at Time of Left Ventricular Assist Device Placement Improves Survival
Bleeding is the most common complication of left ventricular assist device (LVAD) placement. However, excessive transfusion has been linked to heart failure, stroke, and alloimmunization. We compared 90-day outcomes in patients receiving a blood conservation (BCS) versus liberal transfusion strategy during surgery and the subsequent 24 hours.
Source: The Journal of Heart and Lung Transplantation - March 31, 2020 Category: Transplant Surgery Authors: K. Stawiarski, O. Agboola, J. Park, A. Mangi, A. Geirsson, F. Lee, D. Jacoby, L. Bellumkonda, T. Ahmad, J. Chou, J.M. Testani, M. Chen, G. McCloskey, P. Bonde Tags: (356) Source Type: research

Pre-Operative Intracardiac Thrombus is Associated with Increased Risk of Stroke and Death in CF-LVAD Patients
Advanced heart failure predisposes patients to intracardiac thrombus (ICT) formation. There is a paucity of evidence examining the impact of pre-existing left atrial (LA) or left ventricular (LV) thrombi on post-operative outcomes in patients undergoing durable LVAD implantation.
Source: The Journal of Heart and Lung Transplantation - March 31, 2020 Category: Transplant Surgery Authors: C.A. Bravo Carillo, J.A. Fried, G.M. Mondellini, A. Javaid, H.S. Lumish, J.Z. Willey, V.K. Topkara, L. Braghieri, Y. Kaku, L. Witer, H. Takayama, K. Takeda, Y. Naka, N. Uriel, M. Yuzefpolskaya, P.C. Colombo Tags: (349) Source Type: research

Left Atrial Volume after Heart Transplantation - A Predictor of Outcomes?
The left atrium (LA) in heart transplant (HT) recipients is a surgically created chamber from variable portions of donor and recipient. In the non-HT patients there is strong evidence that left atrial volume (LAV) is a robust predictor of cardiovascular outcomes such as atrial fibrillation, stroke, heart failure and cardiovascular death. Thus, we thought to 1) characterize LA size in HT recipients and 2) investigate the implications of “new” LA volume on HT outcomes.
Source: The Journal of Heart and Lung Transplantation - March 31, 2020 Category: Transplant Surgery Authors: Y. Peled, J. Lavee, E. Ram, Y. Kassif, L. Sternik, E. Schwammenthal, R. Klempfner, B. Tzur Tags: (614) Source Type: research

Natural Antibodies and Left Ventricular Assist Device Complications
Left ventricular assist devices (LVAD) are widely used as a support strategy for advanced heart failure. Complications such as thrombosis and bleeding have been linked to LVAD. We observed that LVAD implantation was followed by a sharp increase in serum levels of IgG natural antibodies (Nabs) recognizing oxidation-specific epitopes (OSE) and apoptotic cells. Nabs have been implicated in inflammatory reactions related to atherosclerosis, ischemic stroke and primary graft dysfunction following heart transplantation.
Source: The Journal of Heart and Lung Transplantation - March 31, 2020 Category: Transplant Surgery Authors: S.B. See, D. Onat, E. Hittesdorf, F. McDougan, M. Yuzefpolskaya, A.R. Garan, V.K. Topkara, Y. Naka, H. Takayama, K. Takeda, G.P. Milligan, D. Wencker, S.A. Hall, M. Askar, P. Kimball, G. Wagener, P. Colombo, E. Zorn Tags: (1211) Source Type: research

Ischemic Stroke and Intracranial Hemorrhages during Percutaneous Left Ventricular Assist Device Cardiac Support
Mechanical circulatory support systems for cardiogenic shock and heart failure are associated with ischemic strokes and intracranial hemorrhages. Impella is a percutaneously placed, ventricular assist device for short-term cardiac support. We aimed to study the prevalence of acute neurologic complications during short-term support with Impella.
Source: The Journal of Heart and Lung Transplantation - March 31, 2020 Category: Transplant Surgery Authors: C. Hassett, S. Cho, S. Hasan, R.C. Starling, E. Soltesz, K. Uchino, I. Migdady Tags: (994) Source Type: research

Outpatient Cardiac Palliative Care Reduces Healthcare Utilization
The American Heart Association and American Stroke Association have put forth statement recommending early and continuous access to palliative care for patients with heart disease. There is a national shortage of palliative care providers, and often outpatient palliative care clinics are not profitable to institutions with billing alone. However, early integration of palliative care has been proven to improve the quality of life of patients with advanced heart failure. Other studies have suggested that general palliative care has cost savings to hospital systems.
Source: The Journal of Heart and Lung Transplantation - March 31, 2020 Category: Transplant Surgery Authors: T.A. Barrett Tags: (907) Source Type: research

Janssen Highlights Continued Commitment to Cardiovascular & Metabolic Healthcare Solutions with Late-Breaking Data at the First Fully Virtual American College of Cardiology Scientific Session
RARITAN, N.J., March 20, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that it will unveil late-breaking data from its leading cardiovascular and metabolism portfolio during the virtual American College of Cardiology’s 69th Annual Scientific Session together with the World Congress of Cardiology (ACC.20/WCC) on March 28-30, 2020. Notably, four late-breaking abstracts for XARELTO® (rivaroxaban) will be presented, including data from the Phase 3 VOYAGER PAD study in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization.Click to Tweet: Jan...
Source: Johnson and Johnson - March 20, 2020 Category: Pharmaceuticals Source Type: news

The Impact of Statin Therapy on Neurological Events Following Left Ventricular Assist System Implantation in Advanced Heart Failure
Stroke is a leading cause of disability and death in advanced heart failure patients supported with continuous-flow left ventricular assist systems (CF-LVAS). Statins (HMG-CoA Reductase Inhibitors) reduce the risk of major cardiovascular and neurological events, such as stroke, but their impact has not been evaluated in patients implanted with CF-LVAS. We sought to explore the association between use of statin therapy and subsequent occurrence of neurological events, particularly stroke, following CF-LVAS implantation.
Source: The Journal of Heart and Lung Transplantation - March 3, 2020 Category: Transplant Surgery Authors: Jefferson L. Vieira, Michael Pfeffer, Brian L. Claggett, Garrick C. Stewart, Michael M. Givertz, Lara Coakley, Hari R. Mallidi, Mandeep R. Mehra Tags: Original Clinical Science Source Type: research

First Human Implantation of A Miniaturized Axial Flow Ventricular Assist Device in a Child with End-Stage Heart Failure
Small children with end-stage heart failure who require left ventricular assist device (LVAD) support to heart transplant have limited device options leading to high morbidity and mortality and chronic hospitalization until transplant.1,2 The only FDA-approved durable LVAD for children is a paracorporeal pulsatile device that carries a high stroke risk and lacks portability precluding hospital discharge.1 Temporary paracorporeal continuous flow (CF) devices have also been used off-label for bridge-to-transplant but carry higher mortality, require lengthy paracorporeal cannulas prone to circuit thrombus, and typically requi...
Source: The Journal of Heart and Lung Transplantation - September 10, 2019 Category: Transplant Surgery Authors: Antonio Amodeo, Sergio Filippelli, Gianluigi Perri, Roberta Iacobelli, Rachele Adorisio, Francesca Iodice, Alessandra Rizza, M. Patricia Massicotte, J. Timothy Baldwin, Christopher S.D. Almond Tags: Case Anecdotes, Comments and Opinions Source Type: research

Exercise as a Prescription for Patients with Various Diseases
Publication date: Available online 18 April 2019Source: Journal of Sport and Health ScienceAuthor(s): Xin Luan, Xiangyang Tian, Haixin Zhang, Rui Huang, Na Li, Peijie Chen, Ru WangAbstractA growing understanding of the benefits of exercise over the past few decades has prompted researchers to take an interest in the possibilities of exercise therapy. Because each sport has its own set of characteristics and physiological complications that tend to appear during exercise training, the effects and underlying mechanisms of exercise remain unclear. Thus, the first step in probing exercise effects on different diseases is the s...
Source: Journal of Sport and Health Science - April 20, 2019 Category: Sports Medicine Source Type: research

Pentraxin 3 in Cardiovascular Disease
Giuseppe Ristagno1*, Francesca Fumagalli1, Barbara Bottazzi2, Alberto Mantovani2,3,4, Davide Olivari1, Deborah Novelli1 and Roberto Latini1 1Department of Cardiovascular Research, Mario Negri Institute for Pharmacological Research IRCCS, Milan, Italy 2Humanitas Clinical and Research Center-IRCCS, Milan, Italy 3Humanitas University, Milan, Italy 4The William Harvey Research Institute, Queen Mary University of London, London, United Kingdom The long pentraxin PTX3 is a member of the pentraxin family produced locally by stromal and myeloid cells in response to proinflammatory signals and microbial moieties. The p...
Source: Frontiers in Immunology - April 16, 2019 Category: Allergy & Immunology Source Type: research

Medtronic touts stroke data for HeartWare LVAD
A retrospective analysis of two studies involved the HeartWare left-ventricular assist device Medtronic (NYSE:MDT) acquired in 2016 showed that managing blood pressure reduced the severity of strokes in patients implanted with the HVAD pump. The analysis, of “destination therapy” patients who are not candidates for a heart transplant, took data from the Endurance and Endurance Supplemental studies. Results were presented this week at the annual meeting of the International Society for Heart & Lung Transplantation in London, Medtronic said. The 465-patient Endurance Supplemental study compared 308 patients i...
Source: Mass Device - April 5, 2019 Category: Medical Devices Authors: Brad Perriello Tags: Cardiac Assist Devices Clinical Trials Featured Abbott HeartWare International Inc. Medtronic stjudemedical Thoratec Corp. Source Type: news

Different Risk Factors for Ischemic and Hemorrhagic Stroke on Continuous Flow Left Ventricular Assist Device Support
Patients with end-stage heart failure on left ventricular assist devices are predisposed to stroke. Preoperative factors associated with increased stroke risk are poorly understood.
Source: The Journal of Heart and Lung Transplantation - March 16, 2019 Category: Transplant Surgery Authors: H.K. Lamba, M. Kim, L. Hart, B. Chou, C. Rao, S. Chatterjee, S. Sattee, F. Cheema, A. Civitello, R. Delgado, A. Nair, A. Shafii, G. Loor, T. Rosengart, O. Frazier, J. Morgan Tags: 402 Source Type: research

Carotid Artery Blood Flow and Its Association with Stroke during Left Ventricular Assist Device Support
Left ventricular assist device (LVAD) surgery is a life-prolonging therapy for advanced heart failure (HF). Despite many improvements over the years, LVADs continue to be associated with a high incidence of stroke and other vascular complications such as gastrointestinal bleeding (GIB). At present, the pathogenesis of these complications during LVAD support remains unclear. Abnormal structure and hemodynamics in large arteries are a potential contributor. We hypothesized that structural abnormalities and flow alterations will be significantly associated with stroke and a composite outcome of stroke, GIB, and death in HF pa...
Source: The Journal of Heart and Lung Transplantation - March 16, 2019 Category: Transplant Surgery Authors: M.E. Kiyatkin, A.M. Zuver, A. Gaudig, M. Tiburcio, B.J. McDonnell, M. Yuzefpolskaya, P.C. Colombo, E.J. St öhr, J.Z. Willey Tags: 401 Source Type: research

Mechanical Circulatory Support Patients Awaiting Heart Transplant with Positive AT1R Antibodies Have Acceptable Outcome Post-Heart Transplant
AT1R antibodies (Abs) are known to occur in patients (pts) with heart failure. It has been reported that when AT1R Abs are detected at high levels in mechanical circulatory support (MCS) pts, MCS mortality is increased. AT1R has been associated with the development of an inflammatory state inciting thrombosis. It may be that AT1R Abs are associated with pump thrombosis or even possibly thrombotic stroke. Furthermore, it is not clear whether these pts with MCS and AT1R Abs are at increased risk for post-heart transplant complications such as primary graft dysfunction (PGD) due to the recipients ’ highly inflamed state whi...
Source: The Journal of Heart and Lung Transplantation - March 16, 2019 Category: Transplant Surgery Authors: D.H. Chang, J. Patel, M. Kittleson, D. Geft, S. Dimbil, R. Levine, C. Kawata, L. Czer, J. Moriguchi, D. Ramzy, J.A. Kobashigawa Tags: 502 Source Type: research

Natural Antibodies and Left Ventricular Assist Device Complications
Left ventricular assist devices (LVAD) are widely used as a bridge to heart transplantation or destination therapy for advanced heart failure. However, hemocompatibility-related complications such as pump thrombosis, stroke and bleeding remain frequent. We previously reported that LVAD implantation is followed by a sharp increase in serum levels of IgG natural antibodies (Nabs) recognizing oxidation-specific epitopes (OSE). Nabs have been implicated in inflammatory reactions related to atherosclerosis, ischemic stroke and primary graft dysfunction following heart transplantation.
Source: The Journal of Heart and Lung Transplantation - March 16, 2019 Category: Transplant Surgery Authors: S.B. See, A. Pinsino, N. Kunimune, D. Onat, E. Hittesdorf, A.R. Garan, V.K. Topkara, N. Yoshifumi, H. Takayama, K. Takeda, P.C. Colombo, G. Wagener, M. Yuzefpolskaya, E. Zorn Tags: 606 Source Type: research

Preoperative Computational Fluid Dynamics Simulation of the Best Anastomosis Site and Angle of the Outflow Graft and Ascending Aorta in Continuous Flow Mechanical Assist Devices
Left ventricle assist devices (LVAD) have contributed to improve survival and quality of life in patients with advanced heart failure, in temporary or lifetime support. Despite technological, bio-compatibility and hemodynamic progress, patients with LVAD have still a relevant incidence of adverse events, such as disabling stroke. The outflow cannula (OC) position and angulation, and the anastomosis site seem to modify the flow in the ascending aorta (AA), and consequently the incidence of cerebral embolism and aortic cusps stress.
Source: The Journal of Heart and Lung Transplantation - March 16, 2019 Category: Transplant Surgery Authors: A. Giacomini, A. Esposito, T. Nisi, E. Lapenna, S. Bartesaghi, D. Redaelli, F. Pappalardo, G. Colombo, M. De Bonis Tags: 863 Source Type: research

Positive Correlation between P Wave Analysis and Severity of Heart Failure with Preserved and Reduced Ejection Fraction
Two separate studies by Morris et al. in 1964 and then He at al in 2017 were able to show a direct relationship between P wave analysis and valvular heart disease and ischemic stroke, respectively. We hope to continue this progress by establishing a relationship between P wave morphology, duration, PR interval, and P wave terminal force with the severity of Heart Failure with Preserved Ejection Fraction in our patient population.
Source: The Journal of Heart and Lung Transplantation - March 16, 2019 Category: Transplant Surgery Authors: H. Patel, B. Allen, S. Almhameed, C. Musser Tags: 956 Source Type: research

Use of Pulmonary Arterial Catheters for Management of Acute Decompensated Heart Failure and Peri-Operative Monitoring in Children
Pulmonary arterial catheters (PAC) provide real-time hemodynamic data that has been used to tailor ICU therapies, aid in surgical decision making in adults with ADHF and in predicting right-heart failure (RHF) in adults undergoing LVAD evaluation. Approximately 1/3 of patients develop RVF after LVAD insertion. Patients who required rescue RVAD have increased mortality when compared to planned BiVAD implantation. Right ventricular stroke work index (RVSWI) has been demonstrated to predict RHF in adults.
Source: The Journal of Heart and Lung Transplantation - March 16, 2019 Category: Transplant Surgery Authors: P. Esteso, E.D. Blume, C. VanderPluym, F. Fynn-Thompson, K.P. Daly Tags: 1179 Source Type: research

The Society of Thoracic Surgeons Intermacs Database Annual Report: Evolving Indications, Outcomes, and Scientific Partnerships.
CONCLUSIONS: With the evolution of MCS, patient phenotype and outcomes are also changing over time. CF LVAD support is increasingly being used in the less ill patient phenotype and more patients are supported for destination therapy. Mean survival is now approaching 5 years, but adverse events, especially neurologic events, continue to have a detrimental impact on the success of CF LVAD support. PMID: 30691584 [PubMed - in process]
Source: The Annals of Thoracic Surgery - January 31, 2019 Category: Cardiovascular & Thoracic Surgery Authors: Kormos RL, Cowger J, Pagani FD, Teuteberg JJ, Goldstein DJ, Jacobs JP, Higgins RS, Stevenson LW, Stehlik J, Atluri P, Grady KL, Kirklin JK Tags: Ann Thorac Surg Source Type: research

The Society of Thoracic Surgeons Intermacs Database Annual Report: Evolving Indications, Outcomes, and Scientific Partnerships
ConclusionsWith the evolution of MCS, patient phenotype and outcomes are also changing over time. CF LVAD support is increasingly being used in the less ill patient phenotype and more patients are supported for destination therapy. Mean survival is now approaching 5 years, but adverse events, especially neurologic events, continue to have a detrimental impact on the success of CF LVAD support.
Source: The Annals of Thoracic Surgery - January 26, 2019 Category: Cardiovascular & Thoracic Surgery Source Type: research

Invasive Hemodynamics and Rejection Rates in Patients With Cardiac Sarcoidosis After Heart Transplantation
ConclusionsPatients with CS have similar post-transplant hemodynamics as patients without CS, without evidence of right ventricular dysfunction or pulmonary hypertension. Neither significant rejection nor recurrence of sarcoid in the allograft was observed in this cohort of patients with CS. Survival is similar between patients with CS and those without CS. Heart transplant is a viable strategy in selected patients with CS with excellent outcomes.RésuméIntroductionLa transplantation cardiaque orthotopique (TCO) est de plus en plus utilisée lors d’insuffisance cardiaque terminale liée à une sarcoïdose cardiaque (SC)...
Source: Canadian Journal of Cardiology - July 24, 2018 Category: Cardiology Source Type: research

Medtronic ’s HVAD System Just Became Less Invasive
Medtronic has gained FDA approval for a less-invasive implant approach of its HVAD System, a left ventricular assist device (LVAD) for advanced heart failure patients. The Dublin-based company picked up the technology when it acquired HeartWare in 2016. The firm said the technology is the only LVAD approved in the U.S. for implant via thoracotomy, a small lateral, surgical incision between the patient's ribs on the left side of the chest. FDA approval for HVAD implantation via thoracotomy is based on data from the LATERAL prospective clinical trial, in which 144 patients, with end-stage heart failure who were eligible for ...
Source: MDDI - July 12, 2018 Category: Medical Devices Authors: Omar Ford Tags: Cardiovascular Business Source Type: news

First-in-Man Use of the MVAD Axial-Flow Pump: Long Term Outcome
The use of durable continuous-flow mechanical assist devices provides selected heart failure patients with both symptomatic and functional benefits; however, they are not without potential complications. Infection, thrombosis, stroke and GI bleeding are amongst the most commonly reported problems of left ventricular assist device (LVAD) therapy.1 –3 In addition, LVAD peripherals can be bulky and heavy for the patient to carry, causing joint stress, discomfort and reduced quality of life. Device miniaturization is one design trend that has enabled device implantation in patients with a broader range of body sizes, and whe...
Source: The Journal of Heart and Lung Transplantation - April 24, 2018 Category: Transplant Surgery Authors: Marian Urban, Anfrew Woods, Nicola Robinson-Smith, Guy MacGowan, Chandrika Roysam, Stephan Schueler Source Type: research

First-in-man use of the MVAD axial-flow pump: Long-term outcome
The use of durable continuous-flow mechanical assist devices provides selected heart failure patients with both symptomatic and functional benefits; however, they are not without potential complications. Infection, thrombosis, stroke, and gastrointesinal bleeding are among the most commonly reported problems of left ventricular assist device (LVAD) therapy.1 –3 In addition, LVAD peripherals can be bulky and heavy for the patient to carry, causing joint stress, discomfort, and reduced quality of life.
Source: The Journal of Heart and Lung Transplantation - April 24, 2018 Category: Transplant Surgery Authors: Marian Urban, Anfrew Woods, Nicola Robinson-Smith, Guy MacGowan, Chandrika Roysam, Stephan Schueler Tags: Case Anecdotes, Comments and Opinions Source Type: research

First-in-Man Use of the MVAD Axial-Flow Pump: Long Term Outcome
The use of durable continuous-flow mechanical assist devices provides selected heart failure patients with both symptomatic and functional benefits; however, they are not without potential complications. Infection, thrombosis, stroke and GI bleeding are amongst the most commonly reported problems of left ventricular assist device (LVAD) therapy.1 –3 In addition, LVAD peripherals can be bulky and heavy for the patient to carry, causing joint stress, discomfort and reduced quality of life. Device miniaturization is one design trend that has enabled device implantation in patients with a broader range of body sizes, and whe...
Source: The Journal of Heart and Lung Transplantation - April 24, 2018 Category: Transplant Surgery Authors: Marian Urban, Anfrew Woods, Nicola Robinson-Smith, Guy MacGowan, Chandrika Roysam, Stephan Schueler Source Type: research

Quantifying the Devastation From Stroke During Support With Continuous Flow Pumps: An Intermacs Analysis
Strokes (S) during continuous flow (CF) left ventricular assist device (LVAD) support are a major barrier to extension of the therapy to less ill ambulatory heart failure (HF) patients. We analyzed the incidence, outcome, and impact of major S in the INTERMACS database.
Source: The Journal of Heart and Lung Transplantation - March 31, 2018 Category: Transplant Surgery Authors: J.K. Kirklin, D.C. Naftel, S.L. Myers, F.D. Pagani, L.W. Stevenson, R.L. Kormos, P.C. Colombo Source Type: research

4D Flow MRI in 3D Printed Models of Aorta Grafted With a Ventricular Assist Device Allows Detailed Embolic Trajectory Analysis
Embolic stroke remains an important source of morbidity and mortality in heart failure patients treated with Ventricular Assist Devices (VADs). Decreasing the probability of cranial versus descending aortic embolic trajectory by optimizing the VAD outflow graft position and terminal curvature angle could reduce embolic stroke risk. The goal of this study is to investigate particle trajectories released by a VAD into the aorta, and the effect changes in outflow graft insertion site and terminal curve have on those trajectories.
Source: The Journal of Heart and Lung Transplantation - March 31, 2018 Category: Transplant Surgery Authors: O. Amili, F. Coletti, R. MacIver Source Type: research

PAPi Shows a Stronger Correlation With RAP versus RVSWI in Both HFrEF and HFpEF
This study compares the correlation of RAP with PAPi and RVSWI in patients with heart failure with reduced EF (HFrEF) and those with preserved EF (HFpEF).
Source: The Journal of Heart and Lung Transplantation - March 31, 2018 Category: Transplant Surgery Authors: N. Nair, S. Yang, C. Marzbani, L. Truong, E. Gongora Source Type: research

A Co-Rhythmic, Isolable, Self-Maintenance, Assist (CoRISMA) Device for Class III Heart Failure
Mechanical circulatory support for class III heart failure will be acceptable if it is devoid of any adverse events associated with current LVAD devices. Long blood paths, lack of regular maintainence in a pump bathed in blood and tethered operation may account for some of the adverse events witnessed in current LVADs such as stroke, pump thrombosis and infections. An intra-cardiac device with ability to isolate and clean the interior of the pump, powered without driveline is presented.
Source: The Journal of Heart and Lung Transplantation - March 31, 2018 Category: Transplant Surgery Authors: J. Park, P. Bonde Source Type: research

Early stroke post-heart transplant is associated with decreased survival in children
Over the past several decades significant advances in the management have improved the postoperative mortality with pediatric heart transplant (HTx) recipients now surviving for years after transplant surgery.1 –3 For most children with end-stage heart failure, transplantation is the only effective long term therapy, placing demands on the limited donor pool resulting in long waitlist time, particularly in infants.4 While waiting, mechanical circulatory support as a bridge to transplant often becomes a l ifesaving measure in these terminal heart failure patients.
Source: The Journal of Heart and Lung Transplantation - January 8, 2018 Category: Transplant Surgery Authors: Cheryl Cammock, Swati Choudhry, Chesney M. Castleberry, Noor Al-Hammadi, Pirooz Eghtesady, Charles E. Canter, Kathleen E. Simpson Source Type: research

Anticoagulation with VADs and ECMO: walking the tightrope.
Authors: Raffini L Abstract The evolution of devices for mechanical circulatory support (MCS), including ventricular assist devices (VADs) for patients with heart failure and extracorporeal membrane oxygenation (ECMO) for patients with acute cardiac or respiratory failure, has improved survival for subsets of critically ill children and adults. The devices are intricate and complex, allowing blood to bypass the heart or lungs (or both). As blood flows through these artificial devices, normal hemostasis is disrupted, coagulation is promoted, and in the absence of anticoagulation, a thrombus may form in the device, r...
Source: Hematology ASH Education Program - December 10, 2017 Category: Hematology Tags: Hematology Am Soc Hematol Educ Program Source Type: research

The Impact of Age, Sex, Therapeutic Intent, Race, and Severity of Advanced Heart Failure on Short-term Principal Outcomes in the MOMENTUM 3 Trial
Primary outcomes analysis of the MOMENTUM 3 trial short term cohort demonstrated a higher survival rate free of debilitating stroke and reoperation to replace/remove the device (primary endpoint) in patients receiving the HeartMate 3 (HM3) compared to the HeartMate (HMII). We sought to evaluate the individual and interactive effects of pre-specified patient subgroups (age, sex, race, therapeutic intent (BTT/BTC/DT) and severity of illness) on primary endpoint outcomes in MOMENTUM 3 patients implanted with HM3 and HMII.
Source: The Journal of Heart and Lung Transplantation - November 3, 2017 Category: Transplant Surgery Authors: Daniel J. Goldstein, Mandeep R. Mehra, Yoshifumi Naka, Christopher Salerno, Nir Uriel, David Dean, Akinobu Itoh, Francis D. Pagani, Eric R. Skipper, Geetha Bhat, Nirav Raval, Brian A. Bruckner, Jerry D. Estep, Rebecca Cogswell, Carmelo Milano, Lahn Fendel Source Type: research

Impact of age, sex, therapeutic intent, race and severity of advanced heart failure on short-term principal outcomes in the MOMENTUM 3 trial
In this study we sought to evaluate the individual and interactive effects of pre-specified patient subgroups (age, sex, race, therapeutic intent [bridge to transplant/bridge to candidacy/destination therapy] and severity of illness) on primary end-point outcomes in MOMENTUM 3 patients implanted with HM3 and HMII devices.
Source: The Journal of Heart and Lung Transplantation - November 3, 2017 Category: Transplant Surgery Authors: Daniel J. Goldstein, Mandeep R. Mehra, Yoshifumi Naka, Christopher Salerno, Nir Uriel, David Dean, Akinobu Itoh, Francis D. Pagani, Eric R. Skipper, Geetha Bhat, Nirav Raval, Brian A. Bruckner, Jerry D. Estep, Rebecca Cogswell, Carmelo Milano, Lahn Fendel Tags: Original Clinical Science Source Type: research

How Genomic Research is Changing Heart Care
Genomic testing is most frequently associated with cancer testing, but this area of research is beginning to make an impact on cardiovascular care. A recent scientific statement by the American Heart Association shined a spotlight on how the expressed genome can potentially be used to diagnose diseases and predict who will develop diseases such as coronary artery disease (CAD), stroke, heart failure, and arrhythmias. According to the statement, scientists now have the ability to address disease at many levels that were inaccessible during the past century. This includes the genome, transcriptome, epigenome, proteome, metab...
Source: MDDI - October 27, 2017 Category: Medical Devices Authors: Amanda Pedersen Tags: IVD Cardiovascular Source Type: news

Godly gift for arthritis pain
Big Pharma is at it again… Creating and selling a drug that causes thousands of heart attacks and strokes each year. In 2015, the FDA asked drug makers to strengthen their warning labels. Since then, most have listed their dangerous side effects on the bottle. But one manufacturer thought they didn’t have to warn people about their dangerous drug. They marketed their product as a “unique” breakthrough. They even published studies promising it was “safe for long-term use.” 1 The drug is a 7-year-old arthritis drug called Actemra. It’s made by the Swiss pharmaceutical company Roche. ...
Source: Al Sears, MD Natural Remedies - October 5, 2017 Category: Complementary Medicine Authors: Al Sears Tags: Anti-Aging Source Type: news

ISHLT 2017: Medtronic HVAD trial misses primary endpoint, reports lowered stroke rates
Medtronic (NYSE:MDT) said today that results from the Endurance supplemental trial of its HVAD heart pump system did not meet its primary endpoint, but did report  lowered stroke rates compared to standard treatment. The trial aimed to evaluate the use of the HVAD system, which it picked up along with HeartWare last year, as a destination therapy for patients who require a left ventricular assist device and received improved blood pressure management, the Fridley, Minn.-based company said. Data from the study was presented at the 2017 International Society for Heart and Lung Transplantation Scientific Meeting in San Dieg...
Source: Mass Device - April 5, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Cardiac Assist Devices Cardiovascular Clinical Trials HeartWare International Inc. Medtronic Source Type: news

The Treatment of Patients with Advanced Heart Failure Ineligible for Cardiac Transplantation with the HeartWare Ventricular Assist Device: Results of the ENDURANCE Supplement Trial
The ENDURANCE Trial previously demonstrated non-inferiority of the HeartWare centrifugal flow ventricular assist device system (HVAD) to the control HeartMate II (HMII) axial flow device in 445 end-stage heart failure patients ineligible for heart transplantation. However, the rate of strokes in the HVAD cohort was higher than expected. Analysis of early clinical trial data found that elevated mean arterial blood pressure (MAP) was a highly statistically significant independent risk factor for stroke events.
Source: The Journal of Heart and Lung Transplantation - March 25, 2017 Category: Transplant Surgery Authors: C.A. Milano, J.G. Rogers, A.J. Tatooles, G. Bhat, M.S. Slaughter, E.J. Birks, N.A. Mokadam, C. Mahr, J.S. Miller, V. Jeevanandam, K. Leadley, K.D. Aaronson, F.D. Pagani Source Type: research

Effect of a Multifaceted Team Management Approach on Survival and Stroke Rates in Heartmate 2 Recipients
We report the effect of a comprehensive HM II management strategy on survival and stroke rates.
Source: The Journal of Heart and Lung Transplantation - March 25, 2017 Category: Transplant Surgery Authors: U. Jorde, N. Siddiqi, A. Luke, D.B. Sims, O. Saeed, S.R. Patel, S. Murthy, J. Shin, S. Watts, E. Borukhov, S. Madan, S. Thompson, R. Bello, S. Forest, S. Vukelic, C. Nucci, S. Rangasamy, D. Goldstein Source Type: research

Blood pressure and stroke risk in left ventricular assist devices
Ischemic and hemorrhagic stroke are one of the most devastating outcomes arising from treatment of end-stage congestive heart failure with a left ventricular assist device (LVAD)1. Stroke after LVAD is associated with increased risk of mortality and is a leading cause of not qualifying for transplantation. The risk of stroke is one of many factors limiting more widespread adoption of this technology for end-stage heart failure. The risk factors for stroke in LVAD have been the subject of several studies, with recent infection2 and changes in anti-thrombotics being commonly found3.
Source: The Journal of Heart and Lung Transplantation - December 5, 2014 Category: Transplant Surgery Authors: Joshua Z. Willey Source Type: research